Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | SHFS 0.1324 -61.39% | XXII 0.1977 -8.34% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | RBNE 0.19 -2.56% | YFOR 0.2236 -1.58% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | TQQQ 66.29 -0.20% | TSLL 9.76 -1.21% | VZ 44.66 -1.19% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | GRAB 2.79 -2.11% | AIOK 12.02 182.82% | SQQQ 39.68 0.20% | ONDS 6.2 2.99% | LABT 0.31 -36.67% | AAPL 347.725 -0.14% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | IREN 24.905 -2.37% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | NFLX 65.85 -1.79% | QID 14.55 0.14% | CLRO 3.25 69.27% | WULF 11.32 0.00%
CLClene Inc. logo

Clene Inc. (CLNN)

NASDAQ Capital Market · Currency in USD
$3.88 ▲ +0.00 (+0.00%)
At close: Oct 23, 4:00 PM ET. Market closed.
$3.50 ▼ -0.38 (-9.79%)
Pre-market: Oct 26, 8:17 AM ET

Summary

Previous Close
$3.88
Open
$3.79
Day's Range
$3.77 – $3.97
52 Week Range
$3.02 – $13.50
Volume
21,396
Avg. Volume
96,618
Market Cap
$55.15M
Beta (5Y Monthly)
0.92
PE Ratio (TTM)
--
EPS (TTM)
-$3.19
Earnings Date
Nov 12, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$50.00

Profile: Clene Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
78
CEO
Robert Etherington
Website
clene.com

Clene Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to the discovery, advancement, and market introduction of pioneering therapeutic agents utilizing clean-surfaced nanotechnology (CSN). CNM-Au8 stands as its flagship compound, currently under evaluation across a diverse range of clinical studies. This includes a pivotal Phase 2/3 study intended for regulatory submission in individuals battling amyotrophic lateral sclerosis (ALS).

Earnings

Next report: Thu, Nov 12, 2026
EPS estimate -$0.46 · Revenue est. $70.00K
DateEst.Actual
Aug 14, 2026-$0.37-$1.08Miss
May 14, 2026-$0.50-$0.69Miss
Mar 12, 2026-$0.74-$0.93Miss
Nov 13, 2025-$0.60-$0.85Miss
Aug 14, 2025-$0.49-$0.78Miss
May 7, 2025-$0.95-$0.09Beat

Analyst view

Consensus price target
$50.00 ▲ +1,188.7%
Range $50.00 – $50.00
Rating: Buy
Buy 88% · Hold 13% · Sell 0%

Get free alerts on CLNN and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.